Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Free access | 10.1172/JCI110276

Hormonal Stimulation of Eucaryotic Cell ADP-ribosylation: EFFECT OF THYROTROPIN ON THYROID CELLS

Sebastiano Filetti and Basil Rapoport

The Medical Service, Veterans' Administration Hospital and the University of California Medical Center, San Francisco, California 94121

Find articles by Filetti, S. in: JCI | PubMed | Google Scholar

The Medical Service, Veterans' Administration Hospital and the University of California Medical Center, San Francisco, California 94121

Find articles by Rapoport, B. in: JCI | PubMed | Google Scholar

Published August 1, 1981 - More info

Published in Volume 68, Issue 2 on August 1, 1981
J Clin Invest. 1981;68(2):461–467. https://doi.org/10.1172/JCI110276.
© 1981 The American Society for Clinical Investigation
Published August 1, 1981 - Version history
View PDF
Abstract

The effect of thyrotropin (TSH) on the ADP-ribosylation of endogenous thyroid cell acceptor proteins was examined. Cells were “permeabilized” at 4°C in hypotonic medium and then exposed to [32P]- or [3H-adenine]NAD+. The net incorporation of labeled ADP-ribose was measured by trichloroacetic acid precipitation. TSH (100 mU/ml) enhanced ADP-ribosylation with a maximum effect after 30-60 min in the majority of experiments. TSH stimulation was observed even when the incubation contained 1,000-fold more exogenous NAD+ than the amount of NAD+ contributed by the permeabilized cells, indicating an effect on enzymatic activity rather than an alteration in NAD+ pool size or specific activity. No incorporation of radioactivity from labeled NAD+ was observed in cells not rendered permeable to NAD+ by hypotonic shock. TSH did not increase the rate of disappearance of trichloroacetic-precipitable radioactivity and did not contain intrinsic NAD+ glycohydrolase activity. Alkali and snake venom phosphodiesterase, but not ribonuclease or deoxyribonuclease digestion of trichloroacetic acid precipitable thyroid cell radioactivity, revealed primarily 5′-AMP, consistent with an effect of TSH on mono-ADP ribosylation. Nicotinamide and thymidine (50 mM) inhibited both basal and TSH-stimulated ADP-ribosylation of thyroid cell protein. Dibutyryl cyclic (c)AMP (0.1 mM) inhibited endogenous ADP-ribosylation by ∼35% but had no effect at lower concentrations. 0.5 mM isobutylmethylxanthine inhibited this reaction by ∼60%.

We suggest that TSH enhances thyroid cell ADP-ribosylation by a mechanism independent of cAMP as a second messenger, and that ADP-ribosylation plays a role in the expression of TSH.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 461
page 461
icon of scanned page 462
page 462
icon of scanned page 463
page 463
icon of scanned page 464
page 464
icon of scanned page 465
page 465
icon of scanned page 466
page 466
icon of scanned page 467
page 467
Version history
  • Version 1 (August 1, 1981): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts